Outlook Wealth Advisors LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Outlook Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,428 shares of the biopharmaceutical company's stock, valued at approximately $355,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $49,000. GAMMA Investing LLC increased its stake in Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock valued at $50,000 after buying an additional 350 shares during the last quarter. Toth Financial Advisory Corp purchased a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $57,000. FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $65,000. Finally, Park Place Capital Corp boosted its stake in shares of Halozyme Therapeutics by 828.1% in the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company's stock worth $78,000 after buying an additional 1,209 shares during the last quarter. 97.79% of the stock is owned by institutional investors.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company's stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.70% of the company's stock.

Wall Street Analyst Weigh In

HALO has been the topic of a number of recent analyst reports. JMP Securities lifted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a report on Friday, November 1st. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a "buy" rating in a research report on Friday, January 10th. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday. Finally, JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and upped their price objective for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $60.89.

Halozyme Therapeutics Price Performance

NASDAQ HALO traded down $0.57 during trading hours on Friday, hitting $54.80. The company had a trading volume of 941,026 shares, compared to its average volume of 1,665,325. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The firm has a market capitalization of $6.97 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.40 and a beta of 1.24. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The firm has a 50 day simple moving average of $49.75 and a 200 day simple moving average of $54.07.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.